Bristol-Myers Squibb
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Bristol-Myers Squibb sits in the top decile of US sponsors by registered trial count (#32 of 15,742 sponsors by registered trial count).
Bristol-Myers Squibb: 1,025 sponsored US clinical trials, 73 recruiting.
Bristol-Myers Squibb sponsors 1,025 registered US clinical trials on ClinicalTrials.gov, 73 of them currently recruiting, and 789 completed. 242 of these trials are in Phase 3-4 (later-stage) and 675 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 20 trials.
Top-decile sponsor footprint
Bristol-Myers Squibb ranks in the top decile of sponsors by registered trial count (#32 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
789 of 892 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,025 total, page 13 of 21
PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
NCT01621490
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
NCT01673854
Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib
NCT01593254
Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment
NCT01830205
Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction
NCT01708889
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
NCT01611558
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
NCT01592370
An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy
NCT01585987
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
NCT01616524
Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043 in Healthy Subjects
NCT01605994
Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus
NCT01628692
Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients
NCT01602367
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
NCT01471197
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
NCT01598090
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
NCT01511913
Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors
NCT01629758
Drug Interaction Study of SAR302503 in Patients With Solid Tumor
NCT01585623
Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation
NCT01514864
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
NCT01581203
Single Ascending Dose Safety Study of BMS-962476 in Healthy Subjects and Patients With Elevated Cholesterol on Statins
NCT01587365
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
NCT01573351
Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin
NCT01425970
Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
NCT01460160
Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib
NCT01523171
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
NCT01525810
Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
NCT01386359
Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab
NCT01515189
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
NCT01472081
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
NCT01492504
Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT01471210
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
NCT01492374
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
NCT01393964
Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection
NCT01492426
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
NCT01441973
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
NCT01454102
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
NCT01450761
Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis
NCT01437787
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
NCT01466374
Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus
NCT01471574
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
NCT01489059
Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C
NCT01448044
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
NCT01455090
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
NCT01478048
Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)
NCT01400451
Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients
NCT01332227
Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects
NCT01471717
Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb
NCT01439204
Study Investigating the Pharmacokinetic Interaction Between INX-08189 and Verapamil HCL ER in Healthy Volunteers
NCT01471704
Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects
NCT02034591
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
NCT01420783
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 436 |
| Phase 2 | 239 |
| Phase 3 | 213 |
| Phase 4 | 29 |
Therapeutic Areas
What is open in the Bristol-Myers Squibb pipeline
73 recruiting of 1,025 indexed (7% open); 789 completed (77%).
Phase mix: 242 late (III/IV) vs 675 early (I/II) (early-phase heavy).
Top condition: HIV Infections (20 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Bristol-Myers Squibb: open-pipeline peers nationwide
Peers matched on 1,025 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
Bristol-Myers Squibb sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,025 trials (± recruiting share)
- University of Wisconsin, Madison · 1,039 trials · 15% recruiting
- University of Washington · 1,048 trials · 15% recruiting
- University of Minnesota · 966 trials · 19% recruiting
- Columbia University · 958 trials · 18% recruiting
Sponsors near 7% open enrollment (± trial volume)
- Carol Fabian, MD · 7% recruiting · 14 trials
- Celldex Therapeutics · 7% recruiting · 42 trials
- Kaiser Permanente · 7% recruiting · 294 trials
- Mannkind Corporation · 7% recruiting · 42 trials
Related
What to do with this Bristol-Myers Squibb page
1,025 registered trials is a research-attention snapshot, not an endorsement of Bristol-Myers Squibb or any single study.
- 73 of Bristol-Myers Squibb's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition Bristol-Myers Squibb studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Bristol-Myers Squibb pipeline card: 1,025 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.